Drug major GlaxoSmithKline (GSK) has unethically tested a breast cancer drug on poor patients in India for approval for new drugs in the Europe Union, said a study. According to an investigation by Mumbai-based Centre for Studies in Ethics and Rights, the firm tested lapatinib on patients flouting Indian Council of Medical Research's (ICMR) ethical guidelines.This trial required seriously ill patients who had not received treatment for their condition.
GlaxoSmithKline (NYSE: GSK) provided the following update regarding its application to the U.S. Food and Drug Administration (FDA) for approval of CERVARIX(R), its vaccine to prevent cervical cancer. GSK has submitted its response t... Read Post
Two people working as brokers for a Hyderabad-based pharmaceutical company were Friday arrested in Andhra Pradesh's Guntur district for engaging poor women for unauthorised drug trials, police said. Kommu Karunamma and Shaikh Jameel... Read Post